{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:54:55Z","timestamp":1788310495274,"version":"build-2803163510"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.tranon.2025.102483","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T06:51:54Z","timestamp":1753771914000},"page":"102483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Metformin as a promising therapeutic agent for papillary thyroid cancer: Mechanisms of antitumor and pro-apoptotic activity"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8207-0923","authenticated-orcid":false,"given":"Katarzyna","family":"Wincenciuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7403-6928","authenticated-orcid":false,"given":"Angelika","family":"Buczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4522-4978","authenticated-orcid":false,"given":"Adam Jacek","family":"Kr\u0119towski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-130X","authenticated-orcid":false,"given":"Agnieszka","family":"Adamska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.tranon.2025.102483_bib0001","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/cancers14051336","article-title":"Metformin intervention-a panacea for cancer treatment?","volume":"14","author":"Buczy\u0144ska","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.tranon.2025.102483_bib0002","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1530\/JME-19-0083","article-title":"The role of an anti-diabetic drug metformin in the treatment of endocrine tumors","volume":"63","author":"Thakur","year":"2019","journal-title":"J. Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102483_bib0003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5603\/EP.2018.0014","article-title":"Guidelines of Polish National Societies Diagnostics and treatment of thyroid carcinoma. 2018 update","volume":"69","author":"Jarz\u0105b","year":"2018","journal-title":"Endokrynol. Pol."},{"key":"10.1016\/j.tranon.2025.102483_bib0004","first-page":"1137","article-title":"Choroby tarczycy. W: andrzej szczeklik: choroby wewn\u0119trzne","author":"Jarz\u0105b","year":"2010","journal-title":"Med. Prakt."},{"issue":"1","key":"10.1016\/j.tranon.2025.102483_bib0005","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.tranon.2025.102483_bib0006","doi-asserted-by":"crossref","first-page":"E510","DOI":"10.1210\/jc.2011-1754","article-title":"Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents","volume":"97","author":"Chen","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1\u20132","key":"10.1016\/j.tranon.2025.102483_bib0007","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mce.2014.05.021","article-title":"Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo","volume":"393","author":"Cho","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"issue":"8","key":"10.1016\/j.tranon.2025.102483_bib0008","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1210\/jc.2012-3799","article-title":"Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer","volume":"98","author":"Klubo-Gwiezdzinska","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.tranon.2025.102483_bib0009","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/bcp.13780","article-title":"The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth","volume":"85","author":"Amin","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.tranon.2025.102483_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8759","article-title":"Global burden of thyroid cancer from 1990 to 2017","volume":"3","author":"Deng","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.tranon.2025.102483_bib0011","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/biom12040574","article-title":"Metformin in differentiated thyroid cancer: molecular pathways and its clinical implications","volume":"12","author":"Garc\u00eda-S\u00e1enz","year":"2022","journal-title":"Biomolecules"},{"issue":"22","key":"10.1016\/j.tranon.2025.102483_bib0012","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.4161\/cc.26461","article-title":"Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer","volume":"12","author":"Marini","year":"2013","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.tranon.2025.102483_bib0013","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4158\/EP12244.RA","article-title":"Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer","volume":"19","author":"Klubo-Gwiezdzinska","year":"2013","journal-title":"Endocr. Pract."},{"issue":"11","key":"10.1016\/j.tranon.2025.102483_bib0014","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tranon.2025.102483_bib0015","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.tranon.2025.102483_bib0016","unstructured":"Own elaboration based on Globocan 2022 data 2025 available from: https:\/\/gco.iarc.fr\/today\/en\/. Accessed July 19, 2025."},{"key":"10.1016\/j.tranon.2025.102483_bib0017","unstructured":"Own elaboration based on KRN data 2025 available from: https:\/\/onkologia.org.pl\/pl\/publikacje. Accessed July 19, 2025."},{"issue":"2","key":"10.1016\/j.tranon.2025.102483_bib0018","first-page":"73","article-title":"Metformin- effective antidiabetic medication. Could we make use of its power?","volume":"1","author":"Kujawska-\u0141uczak","year":"2010","journal-title":"Forum Zaburze\u0144 Metab."},{"key":"10.1016\/j.tranon.2025.102483_bib0019","unstructured":"The summary of the medicinal product (various metformin preparations) 2025 available from: www.leki.url.gov.pl. Accessed July 19, 2025."},{"key":"10.1016\/j.tranon.2025.102483_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.arr.2017.08.003","article-title":"Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis","volume":"40","author":"Campbell","year":"2017","journal-title":"Ageing Res. Rev."},{"issue":"7503","key":"10.1016\/j.tranon.2025.102483_bib0021","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Morris AD. Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.tranon.2025.102483_bib0022","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/636927","article-title":"Risk of cancer in diabetes: the effect of metformin","volume":"2013","author":"Malek","year":"2013","journal-title":"ISRN Endocrinol."},{"issue":"33","key":"10.1016\/j.tranon.2025.102483_bib0023","doi-asserted-by":"crossref","first-page":"55622","DOI":"10.18632\/oncotarget.16973","article-title":"Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus: a meta-analysis of cohort studies","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2025.102483_bib0024","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3389\/fonc.2017.00243","article-title":"Metformin: a bridge between diabetes and prostate cancer","volume":"7","author":"Zingales","year":"2017","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.tranon.2025.102483_bib0025","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1158\/0008-5472.CAN-03-0846","article-title":"The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression","volume":"64","author":"Schwartzenberg-Bar-Yoseph","year":"2004","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.tranon.2025.102483_bib0026","doi-asserted-by":"crossref","first-page":"777","DOI":"10.18632\/oncoscience.109","article-title":"Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question","volume":"1","author":"Alfarouk","year":"2014","journal-title":"Oncoscience"},{"issue":"1","key":"10.1016\/j.tranon.2025.102483_bib0027","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JME-16-0134","article-title":"Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo","volume":"58","author":"Shen","year":"2017","journal-title":"J. Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102483_bib0028","first-page":"331","article-title":"Metformin induces TPC-1 cell apoptosis through endoplasmic reticulum stress-associated pathways in vitro and in vivo","volume":"55","author":"Ye","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.tranon.2025.102483_bib0029","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabres.2018.05.023","article-title":"Metformin in cancer","volume":"143","author":"Mallik","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"10","key":"10.1016\/j.tranon.2025.102483_bib0030","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.tips.2018.07.006","article-title":"Metformin as an anticancer agent","volume":"39","author":"Vancura","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"11","key":"10.1016\/j.tranon.2025.102483_bib0031","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.7150\/jca.30659","article-title":"Role of p53 family proteins in metformin anti-cancer activities","volume":"10","author":"Yi","year":"2019","journal-title":"J. Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2025.102483_bib0032","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/ph14030191","article-title":"Metformin increases survival in hypopharyngeal cancer patients with diabetes mellitus: retrospective cohort study and cell-based analysis","volume":"14","author":"Tsou","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tranon.2025.102483_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117717","article-title":"Anticancer mechanisms of metformin: a review of the current evidence","volume":"254","author":"Zhao","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.tranon.2025.102483_bib0034","first-page":"437","article-title":"Biologiczna rola surwiwiny","volume":"12","author":"Karczmarek-Borowska","year":"2008","journal-title":"Wsp\u00f3\u0142czesna Onkol."},{"issue":"3","key":"10.1016\/j.tranon.2025.102483_bib0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/biom12030357","article-title":"Metformin and cancer hallmarks: molecular mechanisms in thyroid, prostate and head and neck cancer models","volume":"12","author":"Morale","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.tranon.2025.102483_bib0036","doi-asserted-by":"crossref","first-page":"427","DOI":"10.18632\/oncotarget.2813","article-title":"DNA damage-induced S and G2\/M cell cycle arrest requires mTORC2-dependent regulation of Chk1","volume":"6","author":"Selvarajah","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2025.102483_bib0037","first-page":"103","article-title":"PI3K-AKT axis in normal lymphoid development and B-cell tumors. Part I","volume":"4","author":"Szyd\u0142owski","year":"2013","journal-title":"Hematol. M\u00e9d."},{"issue":"1","key":"10.1016\/j.tranon.2025.102483_bib0038","article-title":"Metformin: possible use of a diabetes drug in treatment of cancer","volume":"1","author":"Vacheron","year":"2018","journal-title":"Clin. Res. Diabetes Endocrinol."},{"issue":"19","key":"10.1016\/j.tranon.2025.102483_bib0039","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1038\/sj.onc.1210094","article-title":"Regulation of survivin expression by IGF-1\/mTOR signaling","volume":"26","author":"Vaira","year":"2007","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.tranon.2025.102483_bib0040","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1101\/gad.17420111","article-title":"AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function","volume":"25","author":"Hardie","year":"2011","journal-title":"Genes Dev."},{"issue":"6","key":"10.1016\/j.tranon.2025.102483_bib0041","doi-asserted-by":"crossref","first-page":"C1291","DOI":"10.1152\/ajpcell.00136.2010","article-title":"A novel role for AMP-kinase in the regulation of the Na+\/I\u2013symporter and iodide uptake in the rat thyroid gland","volume":"300","author":"Andrade","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"10","key":"10.1016\/j.tranon.2025.102483_bib0042","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1089\/thy.2012.0041","article-title":"AMP-activated protein kinase upregulates glucose uptake in thyroid PCCL3 cells independent of thyrotropin","volume":"22","author":"Andrade","year":"2012","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.tranon.2025.102483_bib0043","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20130134","article-title":"Perspectives of the AMP-activated kinase (AMPK) signalling pathway in thyroid cancer","volume":"34","author":"Andrade","year":"2014","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.tranon.2025.102483_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1114582","article-title":"The role of AMPK in cancer metabolism and its impact on the immunomodulation of the tumor microenvironment","volume":"14","author":"Keerthana","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102483_bib0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2025.102483_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tice.2019.07.007","article-title":"Coenzyme Q10 protects hepatocytes from ischemia reperfusion-induced apoptosis and oxidative stress via regulation of Bax\/Bcl-2\/PUMA and Nrf-2\/FOXO-3\/Sirt-1 signaling pathways","volume":"60","author":"Mahmoud","year":"2019","journal-title":"Tissue Cell"},{"issue":"48","key":"10.1016\/j.tranon.2025.102483_bib0047","doi-asserted-by":"crossref","first-page":"84224","DOI":"10.18632\/oncotarget.20478","article-title":"A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.tranon.2025.102483_bib0048","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4161\/15384047.2014.987021","article-title":"AMPK\/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell","volume":"16","author":"Han","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.tranon.2025.102483_bib0049","first-page":"28","article-title":"Analysis of apoptosis in breast cancer patients","volume":"1","author":"Romanowicz-Makowska","year":"2004","journal-title":"Prz. Menopauzalny"},{"issue":"4","key":"10.1016\/j.tranon.2025.102483_bib0050","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B","article-title":"Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene","volume":"87","author":"Sturm","year":"2000","journal-title":"Int. J. Cancer"},{"issue":"5381","key":"10.1016\/j.tranon.2025.102483_bib0051","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1126\/science.281.5381.1305","article-title":"Death receptors: signaling and modulation","volume":"281","author":"Ashkenazi","year":"1998","journal-title":"Science"},{"issue":"5387","key":"10.1016\/j.tranon.2025.102483_bib0052","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1126\/science.282.5387.290","article-title":"Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis","volume":"282","author":"Bennett","year":"1998","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.tranon.2025.102483_bib0053","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0092-8674(00)81728-6","article-title":"Apoptotic pathways: the roads to ruin","volume":"94","author":"Green","year":"1998","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.tranon.2025.102483_bib0054","first-page":"341","article-title":"Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions","volume":"28","author":"Brzezia\u0144ska","year":"2007","journal-title":"Neuro Endocrinol. Lett."},{"key":"10.1016\/j.tranon.2025.102483_bib0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-6-24","article-title":"The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention","volume":"6","author":"Alao","year":"2007","journal-title":"Mol. Cancer"},{"issue":"13","key":"10.1016\/j.tranon.2025.102483_bib0056","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1158\/0008-5472.CAN-10-1769","article-title":"Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1","volume":"71","author":"Ben Sahra","year":"2011","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.tranon.2025.102483_bib0057","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","article-title":"The Akt-mTOR tango and its relevance to cancer","volume":"8","author":"Hay","year":"2005","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.tranon.2025.102483_bib0058","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1507\/endocrj.50.77","article-title":"Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues","volume":"50","author":"Miyakawa","year":"2003","journal-title":"Endocr. J."},{"issue":"3","key":"10.1016\/j.tranon.2025.102483_bib0059","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9440(10)62295-X","article-title":"Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K\/AKT pathway: regulation of p27kip1 expression and localization","volume":"166","author":"Motti","year":"2005","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.tranon.2025.102483_bib0060","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1210\/en.2006-0937","article-title":"AKT in thyroid tumorigenesis and progression","volume":"148","author":"Shinohara","year":"2007","journal-title":"Endocrinology"},{"issue":"24","key":"10.1016\/j.tranon.2025.102483_bib0061","doi-asserted-by":"crossref","first-page":"21960","DOI":"10.1074\/jbc.M300805200","article-title":"Regulation of the phosphatidylinositol 3-kinase, Akt\/protein kinase B, FRAP\/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland","volume":"278","author":"Suh","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tranon.2025.102483_bib0062","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/OTT.S152818","article-title":"RACKI induces chemotherapy resistance in esophageal carcinoma by upregulating the PI3K\/AKT pathway and Bcl-2 expression","volume":"11","author":"Liu","year":"2018","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.tranon.2025.102483_bib0063","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2025.102483_bib0064","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140585","article-title":"Knockout serum replacement promotes cell survival by preventing BIM from inducing mitochondrial cytochrome C release","volume":"10","author":"Ishii","year":"2015","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.tranon.2025.102483_bib0065","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/bjc.2015.85","article-title":"Mitochondrial apoptosis: killing cancer using the enemy within","volume":"112","author":"Lopez","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2025.102483_bib0066","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/ijms19020448","article-title":"Apoptosis: a target for anticancer therapy","volume":"19","author":"Pfeffer","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.tranon.2025.102483_bib0067","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/00015458.2005.11679794","article-title":"Expression of bcl-2 in papillary thyroid cancers and its prognostic value","volume":"105","author":"Aksoy","year":"2005","journal-title":"Acta Chir. Belg."},{"issue":"6","key":"10.1016\/j.tranon.2025.102483_bib0068","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/ijms18061325","article-title":"New insights in thyroid cancer and p53 family proteins","volume":"18","author":"Manzella","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.tranon.2025.102483_bib0069","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.21073","article-title":"Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations","volume":"103","author":"Quiros","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2025.102483_bib0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1530\/eje.0.1340177","article-title":"Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours","volume":"134","author":"Salvatore","year":"1996","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"10.1016\/j.tranon.2025.102483_bib0071","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.tranon.2025.102483_bib0072","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.7150\/ijms.61944","article-title":"p53-dependent apoptosis is essential for the antitumor effect of paclitaxel response to DNA damage in papillary thyroid carcinoma","volume":"18","author":"Wu","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.tranon.2025.102483_bib0073","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fendo.2012.00133","article-title":"Thyroid cancer cell lines: an overview","volume":"3","author":"Saiselet","year":"2012","journal-title":"Front. Endocrinol."},{"issue":"7","key":"10.1016\/j.tranon.2025.102483_bib0074","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jmcb\/mjz075","article-title":"Inhibition of p53 inhibitors: progress, challenges and perspectives","volume":"11","author":"Sanz","year":"2019","journal-title":"J. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.tranon.2025.102483_bib0075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"7301","key":"10.1016\/j.tranon.2025.102483_bib0076","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1136\/bmj.322.7301.1525","article-title":"The role of apoptosis in autoimmune thyroid disorders and thyroid cancer","volume":"322","author":"Lin","year":"2001","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.tranon.2025.102483_bib0077","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/cancers15061665","article-title":"Clinical implications of mTOR expression in papillary thyroid cancer-a systematic review","volume":"15","author":"Derwich","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2025.102483_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1145082","article-title":"Targeting cyclin D1 as a therapeutic approach for papillary thyroid carcinoma","volume":"13","author":"Cai","year":"2023","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2025.102483_bib0079","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2559.2005.02218.x","article-title":"Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression","volume":"47","author":"Lantsov","year":"2005","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.tranon.2025.102483_bib0080","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3892\/ol.2014.2487","article-title":"BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma","volume":"8","author":"Wang","year":"2014","journal-title":"Oncol. Lett."},{"issue":"11","key":"10.1016\/j.tranon.2025.102483_bib0081","doi-asserted-by":"crossref","first-page":"E2298","DOI":"10.1210\/jc.2014-1779","article-title":"BAG3 promoted starvation-induced apoptosis of thyroid cancer cells via attenuation of autophagy","volume":"99","author":"Li","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.tranon.2025.102483_bib0082","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1210\/jc.2006-1712","article-title":"The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand","volume":"92","author":"Chiappetta","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.tranon.2025.102483_bib0083","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41419-021-03641-8","article-title":"LDHA induces EMT gene transcription and regulates autophagy to promote the metastasis and tumorigenesis of papillary thyroid carcinoma","volume":"12","author":"Hou","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.tranon.2025.102483_bib0084","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/OTT.S227915","article-title":"Metformin inhibits proliferation of human thyroid cancer TPC-1 Cells by decreasing LRP2 to suppress the JNK pathway","volume":"13","author":"He","year":"2020","journal-title":"Onco Targets Ther."},{"issue":"6","key":"10.1016\/j.tranon.2025.102483_bib0085","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.7150\/jca.16584","article-title":"Effects of prolonged exposure to low dose metformin in thyroid cancer cell lines","volume":"8","author":"Kheder","year":"2017","journal-title":"J. Cancer"},{"issue":"16","key":"10.1016\/j.tranon.2025.102483_bib0086","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1158\/1078-0432.CCR-17-3167","article-title":"Metformin targets mitochondrial glycerophosphate dehydrogenase to control rate of oxidative phosphorylation and growth of thyroid cancer in vitro and in vivo","volume":"24","author":"Thakur","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.tranon.2025.102483_bib0087","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109852","article-title":"Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes","volume":"9","author":"Tseng","year":"2014","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.tranon.2025.102483_bib0088","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1089\/thy.2017.0550","article-title":"Protective effect of metformin against thyroid cancer development: a population-based study in Korea","volume":"28","author":"Cho","year":"2018","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.tranon.2025.102483_bib0089","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000437365","article-title":"Metformin is associated with a favorable outcome in diabetic patients with cervical lymph node metastasis of differentiated thyroid cancer","volume":"4","author":"Jang","year":"2015","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.tranon.2025.102483_bib0090","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fendo.2018.00494","article-title":"Efficacy of metformin for benign thyroid nodules in subjects with insulin resistance: a systematic review and meta-analysis","volume":"9","author":"Sui","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.tranon.2025.102483_bib0091","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3892\/ijo.2017.3950","article-title":"Metformin increases sensitivity of osteosarcoma stem cells to cisplatin by inhibiting expression of PKM2","volume":"50","author":"Shang","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.tranon.2025.102483_bib0092","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3389\/fendo.2019.00617","article-title":"The potential effect of metformin on cancer: an umbrella review","volume":"10","author":"Yu","year":"2019","journal-title":"Front. Endocrinol."},{"issue":"9","key":"10.1016\/j.tranon.2025.102483_bib0093","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1158\/1940-6207.CAPR-10-0186","article-title":"Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial","volume":"3","author":"Hosono","year":"2010","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"10.1016\/j.tranon.2025.102483_bib0094","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.18632\/oncotarget.27586","article-title":"An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma","volume":"11","author":"Bever","year":"2020","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.tranon.2025.102483_bib0095","first-page":"321","article-title":"Phase 2 trial of metformin combined with 5-fluorouracil in patients with refractory metastatic colorectal cancer","volume":"15","author":"Miranda","year":"2016","journal-title":"Clin. Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2025.102483_bib0096","article-title":"Results of the safety run-in part of the METAL (METformin in advanced lung cancer) study: a multicentre, open-label phase I\u2013II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer","volume":"2","author":"Morgillo","year":"2017","journal-title":"ESMO Open"},{"issue":"15_suppl","key":"10.1016\/j.tranon.2025.102483_bib0097","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1200\/jco.2010.28.15_suppl.560","article-title":"Gene signature of metformin actions on primary breast cancer within a window of opportunity randomized clinical trial","volume":"28","author":"Hadad","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102483_bib0098","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41523-021-00275-z","article-title":"Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial","volume":"7","author":"Goodwin","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.tranon.2025.102483_bib0099","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ctrv.2017.03.005","article-title":"Metformin and improved treatment outcomes in radiation therapy\u2013a review","volume":"55","author":"Samsuri","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"7","key":"10.1016\/j.tranon.2025.102483_bib0100","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1210\/clinem\/dgae007","article-title":"Enhancing angioinvasion assessment in papillary thyroid cancer via a biomarker panel involving TAC, 8-OHdG, and sortilin","volume":"109","author":"Buczy\u0144ska","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tranon.2025.102483_bib0101","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1330797","article-title":"Examining the clinical relevance of metformin as an antioxidant intervention","volume":"15","author":"Buczy\u0144ska","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102483_bib0102","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-40898-9","article-title":"Clinical significance of oxidative stress markers as angioinvasion and metastasis indicators in papillary thyroid cancer","volume":"13","author":"Buczy\u0144ska","year":"2023","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.tranon.2025.102483_bib0103","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3390\/cancers15092436","article-title":"The relationship between oxidative status and radioiodine treatment qualification among papillary thyroid cancer patients","volume":"15","author":"Buczy\u0144ska","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2025.102483_bib0104","unstructured":"U.S. National Library of Medicine. Evaluation of metformin effect on the fertility of women treated with metformin. ClinicalTrials.gov. Updated July 15, 2024. Accessed July 21, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05468554."},{"key":"10.1016\/j.tranon.2025.102483_bib0105","unstructured":"U.S. National Library of Medicine. Evaluation of metformin and low dose temozolomide in patients with recurrent or refractory glioblastoma. ClinicalTrials.gov. Updated March 1, 2024. Accessed July 21, 2025. https:\/\/clinicaltrials.gov\/study\/NCT03109847."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325002141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325002141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T04:54:57Z","timestamp":1765342497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523325002141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":105,"alternative-id":["S1936523325002141"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102483","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin as a promising therapeutic agent for papillary thyroid cancer: Mechanisms of antitumor and pro-apoptotic activity","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102483","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102483"}}